The Regions that are ahead with vaccines, and that result with declining infections, could theoretically reopen earlier (here the possible map).
Openings in May? The government plan
Bars and restaurants open for lunch and perhaps even for dinner taking advantage of the open spaces, and also for gyms, cinemas, theaters and museums. The draft of the Regions with the measures will be discussed on Thursday, during the State-Regions Conference. The decision on the reopening will probably be taken next week by the Council of Ministers, anticipates Minister Giancarlo Giorgetti.
But Prime Minister Mario Draghi has already reiterated a sine qua non: la health protection of citizens. Health cannot be sacrificed in the name of the economy, this is the premier’s line. And therefore, it will reopen only if the epidemiological curve and the vaccination campaign allow it, after having properly protected the elderly and frail people. Too soon therefore to advance hypotheses on the dates, everything will be decided in the light of the infections.
But among the hypotheses in the field we talk about the possibility to postpone the curfew by 2 hours, from 22 to midnight, of reopen museums, cinemas and theaters with strict rules for distancing, and restarting gyms and swimming pools, perhaps even the stages. “In June we return to the stadium, with the Olimpico in Rome open for Euro 2021, with 25% of the public in the stands” guaranteed the Undersecretary of the Government with responsibility for sport Valentina Vezzali at the Adnkronos examination by the Executive).
The same health minister Roberto Speranza, that the rumors of the building make possible the forced resignation pushed by Draghi, said that, “given that everything will depend on the data, the work especially on reopening for outdoor activities it is a hypothesis that personally convinces me a lot. However, we need to be cautious because taking a step a little longer can make us go back ”.
Why the Johnson & Johnson vaccine was suspended and what changes for Italy
The epidemic in Italy continues to weigh heavily. And the vaccination campaign is proceeding slowly, especially in some regions. After the slowdowns caused by AstraZeneca, now it’s up to J&J. Yesterday there Food & Drug Administration e i Cdc Americans released a statement regarding the new J & J’s Janssen vaccine. As a precautionary measure, “a break” was recommended of the use of this serum.
But Draghi’s team has already assured that the campaign in Italy will continue without suspensions this time. “We will consider whether to give the Johnson & Johnson vaccine to over 60s, and we will do it as soon as the vaccination campaign with this vaccine can be resumed, within 2-3 days, perhaps even less ”, Nicola Magrini, director general of the Italian drug agency, told Porta a Porta. “If it can then be opened for administration by the family doctor, in the pharmacy or in the points of free access that will increase, we will see”.
The epidemic in Italy: the regions with the highest risk
The infections are slightly decreasing, but the situation in the hospitals remains explosive. At the moment, the number of Regions that have an employment rate in intensive care or medical areas above the critical threshold remains high and increasing (15 compared to 14 the previous week). The number of people hospitalized in intensive care is still slightly increasing from 3,716 to 3,743, that of people hospitalized in medical areas goes from 29,231 to 29,337.
However, they still go down slightly there‘incidence (210.8 cases per 100 thousand inhabitants, against 232.74 previously) and theRt average calculated on symptomatic cases, which is fixed at 0,92. Signs that certainly indicate that we are moving towards improvement, but still not enough.
Looking at the risk of the Regions, in the latest ISS monitoring a decrease in the general level of risk is observed, with 4 Regions having a high risk level and 15 moderate ones, of which 4 with a high probability of progression to high risk in the coming weeks and 1 Region and 1 Autonomous Province which have a low risk classification. Here are all the risk levels.
Regions with low risk
- Autonomous Province of Bolzano
Regions with moderate risk
- Emilia Romagna
- Friuli Venezia Giulia
Regions with moderate risk with a high probability of progression
- Autonomous Province of Trento
- Valle d’Aosta.
What do we know about the relationship between Johnson & Johnson vaccine and thrombosis
If we do not continue fast on the vaccine front, the curve will continue to decrease too slowly, and could always rise again due to the easing of containment measures or new Covid variants.
It must be explained that already over 6.8 million people have been immunized with the American Johnson & Johnson single-dose vaccine, and another 9 million doses were exported abroad.
A measure of “extreme precaution” therefore that of the US health authorities, pending the convocation of the Advisory Committee on Immunization Practices tomorrow, the Committee of the CDC for vaccinations, which will have to analyze the cases of thrombosis that have affected 6 vaccinated women.
I 6 cases of thrombosis have concerned women between the ages of 18 and 48. Symptoms emerged between 6 and 13 days later the administration. It should also be noted that only one case out of these 6 was fatal, and another patient is currently in critical condition.
The side effects during the clinical trial they were generally mild or moderate and resolved within a couple of days of vaccination. The most common: injection site pain, headache, fatigue, muscle aches and nausea.
Events of absolute rarity, which however strongly affect the common feeling and the vaccination campaign. This is why the only sensible approach is to look at the numbers, without unnecessary alarmism. The same EMA-European Medicines Agency explained that the safety of J&J, as for the other vaccines, was demonstrated in one clinical study involving over 44 thousand people ages 18 and up in the United States, South Africa and Latin America. The study showed a67% efficacy.
US experts also explained that the “pattern”, ie the structure, of the very rare events observed in patients vaccinated with the Johnson & Johnson vaccine in the USA is similar to that of AstraZeneca in Europe. Too early to make “general statements”, but both J&J and AstraZeneca’s vaccines are viral vectored, the so-called adenoviruses. The “probable cause” of these rare events could be an immune response that is triggered “very rarely” and activates these “extremely rare” clots.
For its part, the US giant Johnson & Johnson admitted to being aware that “thromboembolic events, including those associated with thrombocytopenia, have been reported with Covid-19 vaccines. But a clear causal relationship between these rare events and the Janssen (J&J) Covid-19 vaccine has not been established at the moment. The company still decided to delay the distribution of his serum in Europe.